Product Pipeline
A practical methodology for patient release after tositumomab and (131)i-tositumomab therapy
Journal of Nuclear Medicine
Siegel JA, Kroll S, Regan D, Kaminski MS, and Wahl RL
43/354-63

Adaptation of commercial immunoassays to analysis of complex biological substances
Journal of Immunoassay and Immunochemistry
Lacy MJ, Wang R, Brookshire V, and Floyd K
23/1-32

Binding to CD20 by Anti-B1 Antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines
Cancer Immunology and Immunotherapy
Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, and Yarranton G
51/15-24

Synthesis of bis-spermine dimers that are potent polyamine transport inhibitors
Bioorganic & Medicinal Chemistry Letters
Graminski Gf R, Carlson CL, Ziemer JR, Cai F, Vermeulen NMJ, Vanderwerf SM, and Burns MR
12/35-40

Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy - Conjugate views compared with a hybrid method
Cancer
Koral Kf R, Francis IR, Kroll S, Zasadny KR, Kaminski MS, and Wahl RL
94/1258-63

A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.